Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394052 | 1.00 | CHRNA1 (0.42) | CHRNA1CHRNGCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL16094779 | 0.89 | MAP3K12 (0.43) | CLK4NPY5RKCNH2MAP3K12USP30 | |
| SCHEMBL13738629 | 0.85 | CTSK (0.41) | MAP3K12USP30DRD2DRD3 | |
| SCHEMBL27454689 | 0.85 | CLK4 (0.40) | CHRNA1CHRNGCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL22637348 | 0.85 | DRD2 (0.41) | MAP3K12USP30DRD2DRD3 | |
| SCHEMBL13496621 | 0.84 | CTSK (0.43) | KCNH2MAP3K12MAOAUSP30DRD2 | |
| SCHEMBL3230699 | 0.79 | MAP3K12 (0.53) | MAP3K12EGLN2 | |
| SCHEMBL9792784 | 0.74 | NPY5R (0.45) | CLK4NPY5RKCNH2KDM4CUSP30 | |
| SCHEMBL29500425 | 0.74 | NPY5R (0.45) | CLK4NPY5RKCNH2KDM4CUSP30 | |
| SCHEMBL5564307 | 0.72 | CLK4 (0.53) | CLK4KDM1AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | claimed |
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2010-02-18 | — | — | US | claimed |
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2008048967-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | CA14, HCAR1, CCKAR | CHRNA1 1108/4885CHRNG 458/4885CHRNB1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.